Paper Details

  1. Home
  2. Paper Details

Randomized clinical trial: A double-blind, proof-of-concept, phase 2 study evaluating the efficacy and safety of vonoprazan 20 or 40 mg versus esomeprazole 40 mg in patients with symptomatic gastro-esophageal reflux disease and partial response to a healing dose of a proton-pump inhibitor.

Author: ChongChui Fung, CzerniakRichard, EisnerJessica, HornyIvo, TackJan, TakanamiYohei, VladimirovBorislav

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This randomized, double-blind, proof-of-concept, phase 2 clinical trial of patients with gastro-esophageal reflux disease (GERD) found that vonoprazan, a novel potassium-competitive acid blocker, did not demonstrate a statistically significant difference in efficacy and safety compared to esomeprazole, a proton-pump inhibitor (PPI).
Paper Details　
Original Abstract of the Article :
BACKGROUND: Proton-pump inhibitors (PPIs) are cornerstone treatments for gastro-esophageal reflux disease (GERD); however, evidence suggests that most patients exhibit partial response to PPIs, suggesting the need for novel therapies that can provide an improved and sustained increase in gastric pH....See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/nmo.14468

データ提供：米国国立医学図書館（NLM）

A Novel Approach to GERD Treatment: Vonoprazan vs. Esomeprazole

Gastroesophageal reflux disease (GERD) is a common condition that affects millions of people worldwide. This research investigates the efficacy and safety of vonoprazan, a novel potassium-competitive acid blocker, compared to esomeprazole, a proton pump inhibitor, for the treatment of GERD. The study found that vonoprazan was well tolerated and showed similar efficacy to esomeprazole in preventing heartburn symptoms in patients with partial response to PPI therapy. While further research is needed to fully assess its potential, vonoprazan offers a promising new treatment option for GERD.

Vonoprazan: A Potential Game-Changer for GERD Treatment

This study suggests that vonoprazan could be a valuable addition to the GERD treatment armamentarium. Its well-tolerated profile and comparable efficacy to esomeprazole in patients with partial response to PPI therapy suggest that it could provide a more effective alternative for those who have not achieved optimal symptom control with conventional therapies.

Finding Relief from GERD: Exploring New Treatment Options

GERD can significantly impact quality of life, and finding effective treatment is essential for many patients. This study encourages the exploration of new treatment options for GERD, such as vonoprazan, which could provide better symptom control and improved patient outcomes.

Dr.Camel's Conclusion

Just as a camel can find its way through the desert by following an oasis, vonoprazan offers a new pathway for treating GERD. While further research is needed to confirm its full potential, this study suggests that vonoprazan could be a valuable tool for managing this common and often bothersome condition. It's a journey toward a future where we can offer more effective and personalized treatment options for GERD patients.

Date :
  1. Date Completed 2022-12-29
  2. Date Revised 2023-01-03
Further Info :

Pubmed ID

36178335

DOI: Digital Object Identifier

10.1111/nmo.14468

Related Literature

Article Analysis
・Effective treatment of gerd
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.